Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Takeda's New Invoice Prices More Closely Reflect Price Reductions Than Before
April 1, 2002
-
ARCHIVE REGULATORY NEWS IN BRIEF
April 1, 2002
-
ARCHIVE JIRA Is Enthusiastic about Forming New Medical Device Approval System
April 1, 2002
-
ARCHIVE Sankyo Drastically Reduces "Slide Rate"
April 1, 2002
-
ARCHIVE We Must Do Structural Reform: Mr Takemi, Diet Member
April 1, 2002
-
ARCHIVE Hitachi Medical: Digital Ultrasonic Diagnostic Device, EUB-6500
April 1, 2002
-
ARCHIVE Fukujin to Up Sales to \1 Trillion in 5 Years
April 1, 2002
-
ARCHIVE Profit-making Corps. Not to Join Hospital Operation: Dr Itouji of JMA
April 1, 2002
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
April 1, 2002
-
ARCHIVE Newly Merged Wholesaler Koyo to Get No. 3 Share in Shikoku
April 1, 2002
-
ARCHIVE 26th JMC General Assembly to Invite Citizens to Participate
April 1, 2002
-
ARCHIVE Yamanouchi Ties Up with Metabolex for Discovering Diabetes Drugs
April 1, 2002
-
ARCHIVE Nikken Chemicals to Focus on Drugs
April 1, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 1, 2002
-
ARCHIVE Sawai Sees 23.48% Reduction in NHI Prices
April 1, 2002
-
ARCHIVE Only 10-20% of Patients with Osteoporosis Receiving Treatment: WLJ Seminar
April 1, 2002
-
ARCHIVE Taiyo to Start Strategy to Promote Use of Generics
April 1, 2002
-
ARCHIVE JACCRO Established to Promote Clinical Trials for Cancer
April 1, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
April 1, 2002
-
ARCHIVE RenaScience Offers Renal Disease-Related Genes to Companies
April 1, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…